Drug Therapy [topp]
Severe [qlco]
Hypercholesterolaemia [dsyn]
Patients [podg]
Homozygous [orga]
Familial hypercholesterolaemia [dsyn]
Represent [acty]
Severe [qlco]
Patients [podg]
Spectrum [qnco]
Dyslipidemias [dsyn]
untreated [fndg]
Low Density Lipoprotein Cholesterol [bacs, strd]
Patients [podg]
Range [qnco]
mg dl [qnco]
Patients [podg]
Exhibit [inpr]
Responsive [ftcn]
Responsive [ftcn]
Oral [spco]
Lipid lowering agents [phsu]
Patients [podg]
Heterozygous [orga]
Familial hypercholesterolaemia [dsyn]
untreated [fndg]
mg dl [qnco]
Patients [podg]
Responsive [ftcn]
3-hydroxy-3-methylglutaryl-coenzyme A [bacs, orch]
HMG CoA Reductase [aapp, enzy]
inhibitors [chvf]
Statins [orch, phsu]
Specific [qlco]
Drugs [phsu]
Subset [clas]
Patients [podg]
Severe [qlco]
Refractory [ftcn]
Form [qlco]
Heterozygous [orga]
Familial hypercholesterolaemia [dsyn]
Current Therapy [topp]
Maximal [qlco]
Oral [spco]
treatment goals [inpr]
national [inpr]
Cholesterol [bacs, strd]
educational program [edac]
Guidelines [inpr]
Defined [cnce]
mg dl [qnco]
Prior [tmco]
coronary heart disease [dsyn]
coronary heart disease [dsyn]
Equivalent [qlco]
mg dl [qnco]
Prior [tmco]
coronary heart disease [dsyn]
Coronary heart disease risk [inpr]
Equivalent [qlco]
Current Therapy [topp]
Option [ftcn]
Patients [podg]
Low density lipoprotein apheresis [topp]
Low density lipoprotein apheresis [topp]
Very [qlco]
effective [qlco]
Reducing [qlco]
Patients [podg]
Receive [qlco]
Extracorporeal [spco]
therapy [ftcn]
Costs [qnco]
Limited [ftcn]
Availability [ftcn]
Low density lipoprotein apheresis [topp]
centers [spco]
Recently [tmco]
Lipid lowering drug [phsu]
Currently [tmco]
Investigation [hlca]
proprotein convertase subtilisin/kexin type 9 [gngm]
Play [dora]
Critical [qlco]
controlling [ftcn]
Levels [qlco]
proprotein convertase subtilisin/kexin type 9 [gngm]
ACT [topp]
Enhance [acty]
degradation [ftcn]
Low Density Lipoprotein Receptor [aapp, rcpt]
Protein [aapp, bacs]
inactivation [comd]
proprotein convertase subtilisin/kexin type 9 [gngm]
mice [mamm]
plasma cholesterol [lbpr]
Loss [qnco]
Functional [ftcn]
proprotein convertase subtilisin/kexin type 9 [gngm]
Human [humn]
apparent [idcn]
effects [qlco]
Protease [aapp, enzy, phsu]
Attractive [qlco]
Target [ftcn]
lowering [spco]
Plasma [bdsu]
Alone [qnco]
Combination [qlco]
Statins [orch, phsu]
mipomersen [nnon, phsu]
Apolipoprotein B [aapp, bacs]
synthesis [biof]
Inhibitor [qlco]
lowering [spco]
effective [qlco]
therapy [ftcn]
Concentrations [menp]
Patients [podg]
Homozygous [orga]
Familial hypercholesterolaemia [dsyn]
Receive [qlco]
Lipid lowering drug [phsu]
Including [ftcn]
High dose [qnco]
Statins [orch, phsu]
lomitapide [orch, phsu]
Inhibitor [qlco]
microsomal triglyceride transfer protein [aapp, enzy]
Highly [qlco]
Efficacy [qlco]
Reducing [qlco]
Triglycerides [bacs, lipd]
lomitapide [orch, phsu]
Currently [tmco]
Patients [podg]
Homozygous [orga]
Familial hypercholesterolaemia [dsyn]
Doses [qnco]
mg/d [qnco]
Power [hcpp]
Lipid lowering drug [phsu]
Possibly [qlco]
Superior [spco]
Available [ftcn]
Hypolipidemic Agents [phsu]
Mechanisms [ftcn]
Action [ftcn]
Effectiveness [qlco]
Safety [hcpp]
indication [idcn]
Severe [qlco]
Dyslipidemias [dsyn]
reviewed [inpr]
